News › Industry News, Patient Care

FDA Issues Alert for Counterfeit Botox Across Multiple U.S. States

April 17, 2024
Vial and needle

The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that unsafe counterfeit versions of AbbVie’s Botox were given to consumers for cosmetic purposes in multiple states.

The U.S. Centers for Disease Control and Prevention (CDC) and the FDA are investigating reports of harmful reactions among people who received injections of counterfeit Botox.

As of April 12, a total of 19 people from nine states had reported harmful reactions after receiving Botox injections from unlicensed or untrained individuals, or in non-healthcare settings, such as homes and spas, according to the CDC.

Read more at Reuters >>

View the alert at U.S. Food & Drug Administration >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
    • Allergan Aesthetics Debuts AA Signature in the United States with SKIN360
    • Candela Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • FDA Approves Additional Warning for Kybella Labeling
    • Federal Bill Would Establish New Ownership and Management Requirements for Medical Practices
Advertisement